Kunhong Zhong
- Oncology top 5%
- CAR-T cell therapy research 12
- Cancer Immunotherapy and Biomarkers 4
- Immunology top 10%
- Immune Cell Function and Interaction 5
- Immunotherapy and Immune Responses 4
- Genetics top 10%
- Virus-based gene therapy research 6
- Glioma Diagnosis and Treatment 3
- Genetics top 10%
- Virus-based gene therapy research 6
- Glioma Diagnosis and Treatment 3
-
- SARS-CoV-2 and COVID-19 Research 3
-
- Cancer Research and Treatments 2
- Cited by
- OncologyImmunologyMolecular Biology
- Journals
- SHILAP Revista de lepidopterología (1 paper)PLoS ONE (1 paper)The Science of The Total Environment (1 paper)
- Partner nations
- China
In The Last Decade
Kunhong Zhong
31 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 95
- Oncology 638
- Immunology 338
- Molecular Biology 672
- Genetics 103
- Genetics 179
Countries citing papers authored by Kunhong Zhong
This map shows the geographic impact of Kunhong Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunhong Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunhong Zhong more than expected).
Fields of papers citing papers by Kunhong Zhong
This network shows the impact of papers produced by Kunhong Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunhong Zhong. The network helps show where Kunhong Zhong may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kunhong Zhong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 11 | |
| 3 | 2024 | 6 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 3 | |
| 6 | 2023 | 15 | |
| 7 | 2022 | 13 | |
| 8 | 2022 | 86 | |
| 9 | 2022 | 8 | |
| 10 | CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastomabreakdown → | 2022 | 140 |
| 11 | 2022 | 11 | |
| 12 | 2022 | 14 | |
| 13 | Targeted protein degradation: mechanisms, strategies and applicationbreakdown → | 2022 | 499 |
| 14 | 2021 | 59 | |
| 15 | 2020 | 19 | |
| 16 | 2020 | 30 | |
| 17 | 2019 | 15 | |
| 18 | 2019 | 3 | |
| 19 | 2019 | 13 | |
| 20 | 2018 | 20 |
About Kunhong Zhong
Kunhong Zhong is a scholar working on Immunology, Oncology and Genetics, having authored 32 papers that have together received 1.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (12 papers), Virus-based gene therapy research (6 papers), Immune Cell Function and Interaction (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Immunotherapy and Immune Responses (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Glioma Diagnosis and Treatment (3 papers) and Cancer Research and Treatments (2 papers). The work is most often cited by research in Oncology (638 citations), Immunology (338 citations) and Molecular Biology (672 citations). Kunhong Zhong has collaborated with scholars based in China. Frequent co-authors include Aiping Tong, Lin Zhao, Da Jia, Jia Zhao, Zongliang Zhang, Liangxue Zhou, Xin Tang, Guoqing Wang, Zeng Wang and Gang Guo. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and The Science of The Total Environment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.